Sidechain structure–activity relationships of cyclobutane-based small molecule αvβ3 antagonists
Open Access
- 13 September 2024
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 15 (10) , 3616-3624
Abstract
Cyclobutanes provide a versatile scaffold for the synthesis of small molecule integrin antagonists with good metabolic stability and in vivo tolerability.Keywords
Funding Information
- Prostate Cancer UK (Pilot Grant PA10-01)
- Yorkshire Cancer Research (B002-PhD)
This publication has 43 references indexed in Scilit:
- Integrin-mediated cancer progression as a specific target in clinical therapyBiomedicine & Pharmacotherapy, 2022
- A general chemical principle for creating closure-stabilizing integrin inhibitorsCell, 2022
- Anticancer Water‐Soluble Organoruthenium Complexes: Synthesis and Preclinical EvaluationChemBioChem, 2022
- Inhibition of angiogenesis and tumor progression of MK-0429, an integrin αvβ3 antagonist, on oral squamous cell carcinomaJournal of Cancer Research and Clinical Oncology, 2022
- Cyclobutanes in Small‐Molecule Drug CandidatesChemMedChem, 2022
- An αv‐RGD Integrin Inhibitor Toolbox: Drug Discovery Insight, Challenges and OpportunitiesAngewandte Chemie International Edition, 2018
- A dose escalating phase I study of GLPG0187, a broad spectrum integrin receptor antagonist, in adult patients with progressive high-grade glioma and other advanced solid malignanciesInvestigational New Drugs, 2016
- αv‐Integrin isoform expression in primary human tumors and brain metastasesInternational Journal of Cancer, 2013
- GLPG0187 inhibits progression of established bone metastasis and achieves maximum efficacy when combined with standard-of-care metastatic breast cancer treatmentsBone, 2011
- Design and synthesis of novel platelet fibrinogen receptor antagonists with 2H-1,4-benzoxazine-3(4H)-one scaffold. A systematic studyEuropean Journal of Medicinal Chemistry, 2005